Top-line results were reported today for a new study in Tourette syndrome of the dopamine D1 receptor antagonist ecopipam. This was a study designed to test whether, if someone’s tics improve with 3 months of ecopipam, they continue to have more benefit if you continue it compared to if you switch it for a placebo […]